Great Science. Great Medicine.

Pipeline

Overview 2018-06-06T19:38:54+00:00

Therapeutic Area

Drug/ Target

Indication
Preclinical
Phase I
Phase II
Phase III

Anticipated Milestones

Anticipated Milestones
Complete enrollment mid 2018
Patient enrollment ongoing
Initiate clinical studies by end of 2018
Anticipated Milestones

Launched studies for Primary FSGS: non-nephrotic and nephrotic syndrome

Vifor has future option

Anticipated Milestones

Explore Partnering Options to Advance Program in IBD

Progress in TH17 Disease

Drug: Indication (Target)
Pre
PI
PII
PIII
Anticipated Milestones

Advance CCX872 in combination with other therapies